Session Type: 1-hour Mini Oral Flash
Session Title: 1-hour Mini Oral Flash
Authors(s): A. Cuénod (1, 2), B. Bayraktar (3), M. Aerni (4), C. Bagutti (5), C. Maffioli (6), D. Ziegler (7), C. Beisert Carneiro (8), M. Wootton (9), J. Logan (10), M. Demirci (11), G. Jost (12), S. Pranghofer (13), S. Kittl (14), R. Lienhard (15), C. Lang (16), O. Nolte (17), C. Casanova (18), M. Oberle (19), A. Riat (20), A. Coste (21), B. Rodríguez-Sánchez (22), D. Van Dam (23), R. Rentenaar (24), G.A. Kampinga (25), J. Moran-Gilad (26), M. Marschal (27), P. Damborg (28), M. Pedersen (29), T.G. Jensen (30), J. Hurych (31), J. Hrabak (32), I. Marekovic (33), C. Lammens (34), E. Willems (35), S. Jungmann (36), V. Pflüger (37), A. Egli (1, 2)
Authors Affiliations(s): (1) Applied Microbiology Research, Department of Biomedicine, University of Basel, Switzerland, (2) Division of Clinical Bacteriology and Mycology, University Hospital Basel, Switzerland, (3) University of Health Sciences, Sisli Hamidiye Etfal Teaching and Research Hospital, Turkey, (4) Labor Team W, Switzerland, (5) Cantonal laboratory Basel-Stadt, Switzerland, (6) MCL laboratories, Switzerland, (7) Eurofins Scientific AG, Switzerland, (8) University Hospital Freiburg, Germany, (9) University Hospital of Wales, United Kingdom, (10) Public Health England, United Kingdom, (11) Beykent University, Faculty of Medicine, Department of Medical Microbiology, Turkey, (12) Dianalabs, Switzerland, (13) Bioanalytica, Switzerland, (14) Institute of Veterinary Bacteriology, Switzerland, (15) ADMED Microbiologie, Switzerland, (16) Viollier AG, Switzerland, (17) Zentrum für Labormedizin, Switzerland, (18) Institute for Infectious Diseases, Switzerland, (19) Cantonal Hospital Aarau, Switzerland, (20) University Hospital Geneva, Switzerland, (21) Centre hospitalier universitaire vaudois, Switzerland, (22) Hospital General Universitario Gregorio Maranon, Spain, (23) Arts-microbioloog Zuyderland MC, Netherlands, (24) UMC Utrecht, Netherlands, (25) University of Groningen, University Medical Center Groningen, Netherlands, (26) Ben Gurion University of the Negev, Israel, (27) Institute of Medical Microbiology and Hygiene, University of Tübingen, Germany, (28) University of Copenhagen, Department of Veterinary and Animal Sciences, Denmark, (29) Department of Clinical Microbiology, Hvidovre Hospital, Denmark, (30) Department of Clinical Microbiology, Odense University Hospital, Denmark, (31) 2nd Faculty of Medicine, Charles University and Motol University Hospital, Czech Republic, (32) Biomedical Center, Faculty of Medicine in Pilsen, Charles University, Czech Republic, (33) University Hospital Centre Zagreb, Croatia, (34) Medical Microbiology, University of Antwerp, Belgium, (35) Clinical Laboratory AZNikolaas, Belgium, (36) Austrian Agency for Health and Food Safety, Austria, (37) Mabritec AG, Switzerland
Background:
MALDI-TOF MS is the most widely used tool for bacterial species identification in clinical diagnostics. Important challenges remain, which arise from incomplete databases and insufficient mass spectral quality. We identified the number of detected marker masses, reproducibility and measurement precision to be associated with spectral quality. We aimed to assess the spectral quality in diagnostic laboratories and what laboratory procedures impact spectral quality.
Methods:We sent 47 bacterial strains to 36 laboratories in 12 countries. The strains were routinely measured on 41 MALDI-TOF MS devices. We assessed the mass spectral quality of this dataset using well defined quality features. Species identification was performed using the microflex Biotyper database or the VitekMS database and using a ribosomal marker based approach. In order to elaborate which laboratory practices are associated with high mass spectral quality, each laboratory has answered a questionnaire focussing on laboratory procedures.
Results:We received 5,134 spectra measured on 41 devices at the participating laboratories. We observed major differences between the devices in spectral quality considering the number of marker masses detected (e.g. device 7: median=25; Interquartile range (IQR)=[20,28] vs. device 32: median=5, IQR=[3,14]), reproducibility between technical replicates (device 11: median=86%, IQR=[81%,91%] vs. device 12: lowest: median=55%, IQR=[45%,68%]) and measurement error (device 11: median=143ppm, IQR=[109ppm,192ppm] vs. device 41: median=588ppm, IQR=[533ppm,635ppm]) (Figure 1). We observed a correlation of spectral quality and the ability of MALDI-TOF MS to distinguish between closely related species within the genus Klebsiella (Figure 2). We observed a higher number of detected marker masses for laboratories performing regular hardware service compared to laboratories which do not (median=16; IQR=[13,20] vs. median=15, IQR=[11,18]), and a lower number of detected marker masses for strains cultured under procedure A, compared to other culturing procedures (median=11; IQR=[6,15.75] vs. median=17, IQR=[13,20]), (p-values<0.0001, unpaired wilcoxon-rank test) (Figure 3).
Conclusions:We have shown that laboratory procedures impact spectral quality. Based on the data acquired within this study, we have developed protocols, likely able to increase mass spectral quality. This will be assessed in follow-up measurements at all laboratories.
Keyword(s): MALDI-TOF MS, Quality Control, Bacterial Species IdentificationSession Type: 1-hour Mini Oral Flash
Session Title: 1-hour Mini Oral Flash
Authors(s): A. Cuénod (1, 2), B. Bayraktar (3), M. Aerni (4), C. Bagutti (5), C. Maffioli (6), D. Ziegler (7), C. Beisert Carneiro (8), M. Wootton (9), J. Logan (10), M. Demirci (11), G. Jost (12), S. Pranghofer (13), S. Kittl (14), R. Lienhard (15), C. Lang (16), O. Nolte (17), C. Casanova (18), M. Oberle (19), A. Riat (20), A. Coste (21), B. Rodríguez-Sánchez (22), D. Van Dam (23), R. Rentenaar (24), G.A. Kampinga (25), J. Moran-Gilad (26), M. Marschal (27), P. Damborg (28), M. Pedersen (29), T.G. Jensen (30), J. Hurych (31), J. Hrabak (32), I. Marekovic (33), C. Lammens (34), E. Willems (35), S. Jungmann (36), V. Pflüger (37), A. Egli (1, 2)
Authors Affiliations(s): (1) Applied Microbiology Research, Department of Biomedicine, University of Basel, Switzerland, (2) Division of Clinical Bacteriology and Mycology, University Hospital Basel, Switzerland, (3) University of Health Sciences, Sisli Hamidiye Etfal Teaching and Research Hospital, Turkey, (4) Labor Team W, Switzerland, (5) Cantonal laboratory Basel-Stadt, Switzerland, (6) MCL laboratories, Switzerland, (7) Eurofins Scientific AG, Switzerland, (8) University Hospital Freiburg, Germany, (9) University Hospital of Wales, United Kingdom, (10) Public Health England, United Kingdom, (11) Beykent University, Faculty of Medicine, Department of Medical Microbiology, Turkey, (12) Dianalabs, Switzerland, (13) Bioanalytica, Switzerland, (14) Institute of Veterinary Bacteriology, Switzerland, (15) ADMED Microbiologie, Switzerland, (16) Viollier AG, Switzerland, (17) Zentrum für Labormedizin, Switzerland, (18) Institute for Infectious Diseases, Switzerland, (19) Cantonal Hospital Aarau, Switzerland, (20) University Hospital Geneva, Switzerland, (21) Centre hospitalier universitaire vaudois, Switzerland, (22) Hospital General Universitario Gregorio Maranon, Spain, (23) Arts-microbioloog Zuyderland MC, Netherlands, (24) UMC Utrecht, Netherlands, (25) University of Groningen, University Medical Center Groningen, Netherlands, (26) Ben Gurion University of the Negev, Israel, (27) Institute of Medical Microbiology and Hygiene, University of Tübingen, Germany, (28) University of Copenhagen, Department of Veterinary and Animal Sciences, Denmark, (29) Department of Clinical Microbiology, Hvidovre Hospital, Denmark, (30) Department of Clinical Microbiology, Odense University Hospital, Denmark, (31) 2nd Faculty of Medicine, Charles University and Motol University Hospital, Czech Republic, (32) Biomedical Center, Faculty of Medicine in Pilsen, Charles University, Czech Republic, (33) University Hospital Centre Zagreb, Croatia, (34) Medical Microbiology, University of Antwerp, Belgium, (35) Clinical Laboratory AZNikolaas, Belgium, (36) Austrian Agency for Health and Food Safety, Austria, (37) Mabritec AG, Switzerland
Background:
MALDI-TOF MS is the most widely used tool for bacterial species identification in clinical diagnostics. Important challenges remain, which arise from incomplete databases and insufficient mass spectral quality. We identified the number of detected marker masses, reproducibility and measurement precision to be associated with spectral quality. We aimed to assess the spectral quality in diagnostic laboratories and what laboratory procedures impact spectral quality.
Methods:We sent 47 bacterial strains to 36 laboratories in 12 countries. The strains were routinely measured on 41 MALDI-TOF MS devices. We assessed the mass spectral quality of this dataset using well defined quality features. Species identification was performed using the microflex Biotyper database or the VitekMS database and using a ribosomal marker based approach. In order to elaborate which laboratory practices are associated with high mass spectral quality, each laboratory has answered a questionnaire focussing on laboratory procedures.
Results:We received 5,134 spectra measured on 41 devices at the participating laboratories. We observed major differences between the devices in spectral quality considering the number of marker masses detected (e.g. device 7: median=25; Interquartile range (IQR)=[20,28] vs. device 32: median=5, IQR=[3,14]), reproducibility between technical replicates (device 11: median=86%, IQR=[81%,91%] vs. device 12: lowest: median=55%, IQR=[45%,68%]) and measurement error (device 11: median=143ppm, IQR=[109ppm,192ppm] vs. device 41: median=588ppm, IQR=[533ppm,635ppm]) (Figure 1). We observed a correlation of spectral quality and the ability of MALDI-TOF MS to distinguish between closely related species within the genus Klebsiella (Figure 2). We observed a higher number of detected marker masses for laboratories performing regular hardware service compared to laboratories which do not (median=16; IQR=[13,20] vs. median=15, IQR=[11,18]), and a lower number of detected marker masses for strains cultured under procedure A, compared to other culturing procedures (median=11; IQR=[6,15.75] vs. median=17, IQR=[13,20]), (p-values<0.0001, unpaired wilcoxon-rank test) (Figure 3).
Conclusions:We have shown that laboratory procedures impact spectral quality. Based on the data acquired within this study, we have developed protocols, likely able to increase mass spectral quality. This will be assessed in follow-up measurements at all laboratories.
Keyword(s): MALDI-TOF MS, Quality Control, Bacterial Species Identification
Session Type: 1-hour Mini Oral Flash
Session Title: 1-hour Mini Oral Flash
Authors(s): A. Cuénod (1, 2), B. Bayraktar (3), M. Aerni (4), C. Bagutti (5), C. Maffioli (6), D. Ziegler (7), C. Beisert Carneiro (8), M. Wootton (9), J. Logan (10), M. Demirci (11), G. Jost (12), S. Pranghofer (13), S. Kittl (14), R. Lienhard (15), C. Lang (16), O. Nolte (17), C. Casanova (18), M. Oberle (19), A. Riat (20), A. Coste (21), B. Rodríguez-Sánchez (22), D. Van Dam (23), R. Rentenaar (24), G.A. Kampinga (25), J. Moran-Gilad (26), M. Marschal (27), P. Damborg (28), M. Pedersen (29), T.G. Jensen (30), J. Hurych (31), J. Hrabak (32), I. Marekovic (33), C. Lammens (34), E. Willems (35), S. Jungmann (36), V. Pflüger (37), A. Egli (1, 2)
Authors Affiliations(s): (1) Applied Microbiology Research, Department of Biomedicine, University of Basel, Switzerland, (2) Division of Clinical Bacteriology and Mycology, University Hospital Basel, Switzerland, (3) University of Health Sciences, Sisli Hamidiye Etfal Teaching and Research Hospital, Turkey, (4) Labor Team W, Switzerland, (5) Cantonal laboratory Basel-Stadt, Switzerland, (6) MCL laboratories, Switzerland, (7) Eurofins Scientific AG, Switzerland, (8) University Hospital Freiburg, Germany, (9) University Hospital of Wales, United Kingdom, (10) Public Health England, United Kingdom, (11) Beykent University, Faculty of Medicine, Department of Medical Microbiology, Turkey, (12) Dianalabs, Switzerland, (13) Bioanalytica, Switzerland, (14) Institute of Veterinary Bacteriology, Switzerland, (15) ADMED Microbiologie, Switzerland, (16) Viollier AG, Switzerland, (17) Zentrum für Labormedizin, Switzerland, (18) Institute for Infectious Diseases, Switzerland, (19) Cantonal Hospital Aarau, Switzerland, (20) University Hospital Geneva, Switzerland, (21) Centre hospitalier universitaire vaudois, Switzerland, (22) Hospital General Universitario Gregorio Maranon, Spain, (23) Arts-microbioloog Zuyderland MC, Netherlands, (24) UMC Utrecht, Netherlands, (25) University of Groningen, University Medical Center Groningen, Netherlands, (26) Ben Gurion University of the Negev, Israel, (27) Institute of Medical Microbiology and Hygiene, University of Tübingen, Germany, (28) University of Copenhagen, Department of Veterinary and Animal Sciences, Denmark, (29) Department of Clinical Microbiology, Hvidovre Hospital, Denmark, (30) Department of Clinical Microbiology, Odense University Hospital, Denmark, (31) 2nd Faculty of Medicine, Charles University and Motol University Hospital, Czech Republic, (32) Biomedical Center, Faculty of Medicine in Pilsen, Charles University, Czech Republic, (33) University Hospital Centre Zagreb, Croatia, (34) Medical Microbiology, University of Antwerp, Belgium, (35) Clinical Laboratory AZNikolaas, Belgium, (36) Austrian Agency for Health and Food Safety, Austria, (37) Mabritec AG, Switzerland
Background:
MALDI-TOF MS is the most widely used tool for bacterial species identification in clinical diagnostics. Important challenges remain, which arise from incomplete databases and insufficient mass spectral quality. We identified the number of detected marker masses, reproducibility and measurement precision to be associated with spectral quality. We aimed to assess the spectral quality in diagnostic laboratories and what laboratory procedures impact spectral quality.
Methods:We sent 47 bacterial strains to 36 laboratories in 12 countries. The strains were routinely measured on 41 MALDI-TOF MS devices. We assessed the mass spectral quality of this dataset using well defined quality features. Species identification was performed using the microflex Biotyper database or the VitekMS database and using a ribosomal marker based approach. In order to elaborate which laboratory practices are associated with high mass spectral quality, each laboratory has answered a questionnaire focussing on laboratory procedures.
Results:We received 5,134 spectra measured on 41 devices at the participating laboratories. We observed major differences between the devices in spectral quality considering the number of marker masses detected (e.g. device 7: median=25; Interquartile range (IQR)=[20,28] vs. device 32: median=5, IQR=[3,14]), reproducibility between technical replicates (device 11: median=86%, IQR=[81%,91%] vs. device 12: lowest: median=55%, IQR=[45%,68%]) and measurement error (device 11: median=143ppm, IQR=[109ppm,192ppm] vs. device 41: median=588ppm, IQR=[533ppm,635ppm]) (Figure 1). We observed a correlation of spectral quality and the ability of MALDI-TOF MS to distinguish between closely related species within the genus Klebsiella (Figure 2). We observed a higher number of detected marker masses for laboratories performing regular hardware service compared to laboratories which do not (median=16; IQR=[13,20] vs. median=15, IQR=[11,18]), and a lower number of detected marker masses for strains cultured under procedure A, compared to other culturing procedures (median=11; IQR=[6,15.75] vs. median=17, IQR=[13,20]), (p-values<0.0001, unpaired wilcoxon-rank test) (Figure 3).
Conclusions:We have shown that laboratory procedures impact spectral quality. Based on the data acquired within this study, we have developed protocols, likely able to increase mass spectral quality. This will be assessed in follow-up measurements at all laboratories.
Keyword(s): MALDI-TOF MS, Quality Control, Bacterial Species IdentificationSession Type: 1-hour Mini Oral Flash
Session Title: 1-hour Mini Oral Flash
Authors(s): A. Cuénod (1, 2), B. Bayraktar (3), M. Aerni (4), C. Bagutti (5), C. Maffioli (6), D. Ziegler (7), C. Beisert Carneiro (8), M. Wootton (9), J. Logan (10), M. Demirci (11), G. Jost (12), S. Pranghofer (13), S. Kittl (14), R. Lienhard (15), C. Lang (16), O. Nolte (17), C. Casanova (18), M. Oberle (19), A. Riat (20), A. Coste (21), B. Rodríguez-Sánchez (22), D. Van Dam (23), R. Rentenaar (24), G.A. Kampinga (25), J. Moran-Gilad (26), M. Marschal (27), P. Damborg (28), M. Pedersen (29), T.G. Jensen (30), J. Hurych (31), J. Hrabak (32), I. Marekovic (33), C. Lammens (34), E. Willems (35), S. Jungmann (36), V. Pflüger (37), A. Egli (1, 2)
Authors Affiliations(s): (1) Applied Microbiology Research, Department of Biomedicine, University of Basel, Switzerland, (2) Division of Clinical Bacteriology and Mycology, University Hospital Basel, Switzerland, (3) University of Health Sciences, Sisli Hamidiye Etfal Teaching and Research Hospital, Turkey, (4) Labor Team W, Switzerland, (5) Cantonal laboratory Basel-Stadt, Switzerland, (6) MCL laboratories, Switzerland, (7) Eurofins Scientific AG, Switzerland, (8) University Hospital Freiburg, Germany, (9) University Hospital of Wales, United Kingdom, (10) Public Health England, United Kingdom, (11) Beykent University, Faculty of Medicine, Department of Medical Microbiology, Turkey, (12) Dianalabs, Switzerland, (13) Bioanalytica, Switzerland, (14) Institute of Veterinary Bacteriology, Switzerland, (15) ADMED Microbiologie, Switzerland, (16) Viollier AG, Switzerland, (17) Zentrum für Labormedizin, Switzerland, (18) Institute for Infectious Diseases, Switzerland, (19) Cantonal Hospital Aarau, Switzerland, (20) University Hospital Geneva, Switzerland, (21) Centre hospitalier universitaire vaudois, Switzerland, (22) Hospital General Universitario Gregorio Maranon, Spain, (23) Arts-microbioloog Zuyderland MC, Netherlands, (24) UMC Utrecht, Netherlands, (25) University of Groningen, University Medical Center Groningen, Netherlands, (26) Ben Gurion University of the Negev, Israel, (27) Institute of Medical Microbiology and Hygiene, University of Tübingen, Germany, (28) University of Copenhagen, Department of Veterinary and Animal Sciences, Denmark, (29) Department of Clinical Microbiology, Hvidovre Hospital, Denmark, (30) Department of Clinical Microbiology, Odense University Hospital, Denmark, (31) 2nd Faculty of Medicine, Charles University and Motol University Hospital, Czech Republic, (32) Biomedical Center, Faculty of Medicine in Pilsen, Charles University, Czech Republic, (33) University Hospital Centre Zagreb, Croatia, (34) Medical Microbiology, University of Antwerp, Belgium, (35) Clinical Laboratory AZNikolaas, Belgium, (36) Austrian Agency for Health and Food Safety, Austria, (37) Mabritec AG, Switzerland
Background:
MALDI-TOF MS is the most widely used tool for bacterial species identification in clinical diagnostics. Important challenges remain, which arise from incomplete databases and insufficient mass spectral quality. We identified the number of detected marker masses, reproducibility and measurement precision to be associated with spectral quality. We aimed to assess the spectral quality in diagnostic laboratories and what laboratory procedures impact spectral quality.
Methods:We sent 47 bacterial strains to 36 laboratories in 12 countries. The strains were routinely measured on 41 MALDI-TOF MS devices. We assessed the mass spectral quality of this dataset using well defined quality features. Species identification was performed using the microflex Biotyper database or the VitekMS database and using a ribosomal marker based approach. In order to elaborate which laboratory practices are associated with high mass spectral quality, each laboratory has answered a questionnaire focussing on laboratory procedures.
Results:We received 5,134 spectra measured on 41 devices at the participating laboratories. We observed major differences between the devices in spectral quality considering the number of marker masses detected (e.g. device 7: median=25; Interquartile range (IQR)=[20,28] vs. device 32: median=5, IQR=[3,14]), reproducibility between technical replicates (device 11: median=86%, IQR=[81%,91%] vs. device 12: lowest: median=55%, IQR=[45%,68%]) and measurement error (device 11: median=143ppm, IQR=[109ppm,192ppm] vs. device 41: median=588ppm, IQR=[533ppm,635ppm]) (Figure 1). We observed a correlation of spectral quality and the ability of MALDI-TOF MS to distinguish between closely related species within the genus Klebsiella (Figure 2). We observed a higher number of detected marker masses for laboratories performing regular hardware service compared to laboratories which do not (median=16; IQR=[13,20] vs. median=15, IQR=[11,18]), and a lower number of detected marker masses for strains cultured under procedure A, compared to other culturing procedures (median=11; IQR=[6,15.75] vs. median=17, IQR=[13,20]), (p-values<0.0001, unpaired wilcoxon-rank test) (Figure 3).
Conclusions:We have shown that laboratory procedures impact spectral quality. Based on the data acquired within this study, we have developed protocols, likely able to increase mass spectral quality. This will be assessed in follow-up measurements at all laboratories.
Keyword(s): MALDI-TOF MS, Quality Control, Bacterial Species Identification